Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1634/theoncologist.2017-0682 http://scihub22266oqcxt.onion/10.1634/theoncologist.2017-0682 C5896716!5896716!29371475     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Oncologist 2018 ; 23 (4): 399-e33 Nephropedia Template TP {{tp|p=29371475|t=2018. Chemoprevention in Patients with Peutz?Jeghers Syndrome: Lessons Learned |pdf=|usr=}}{{29371475}} gab.com Text Chemoprevention in Patients with Peutz Jeghers Syndrome: Lessons Learned JO: Oncologist http://www.kidney.de/pget.php?&tw=1&pmid=29371475 #FOAvip Lessons Learned.Motivating patients to enroll in chemopreventive studies is challenging.Chemoprevention with toxic drugs is not feasible. Background.LKB1 mutations are the underlying genetic abnormality causing Peutz?Jeghers syndrome (PJS) and are a potential target for everolimus. In this phase II study, the efficacy of everolimus on polyp and tumor growth in PJS patients was investigated. Methods.Adult patients with a proven LKB1 mutation and who were suitable for everolimus treatment were included in two different PJS cohorts: (a) patients with unresectable malignancies and (b) patients with high?risk polyps. Treatment in both groups was oral everolimus, 10 mg daily. Response rates were primary endpoints for both cohorts. Results.Between October 2011 and April 2016, only two patients were enrolled, one in each cohort. A 49?year?old patient with advanced pancreatic cancer in cohort 1 was progressive after 2 months. A 52?year?old male patient in cohort 2 experienced severe toxicity and refused treatment after 4 months, even though endoscopy suggested stabilization of polyps. Adverse events included dental inflammations, mucositis, and rash. In 2016, the trial was aborted for lack of accrual, despite extensive accrual efforts in an area where PJS is highly prevalent and care is highly centralized. Conclusion.Due to accrual problems, no conclusions can be drawn about the value of everolimus in PJS treatment, questioning the feasibility of this agent for chemoprevention. Twit Text FOAVip Chemoprevention in Patients with Peutz Jeghers Syndrome: Lessons Learned ????Oncologist http://www.kidney.de/pget.php?&tw=1&pmid=29371475 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29371475 #FOAvip English Wikipedia <ref>{{Cite pmid|29371475}}</ref> Chemoprevention in Patients with Peutz?Jeghers Syndrome: Lessons Learned #MMPMID29371475 de Brabander J; Eskens FA; Korsse SE; Dekker E; Dewint P; van Leerdam ME; van Eeden S; Klümpen H Oncologist 2018[Apr]; 23 (4): 399-e33 PMID29371475show ga Lessons Learned.Motivating patients to enroll in chemopreventive studies is challenging.Chemoprevention with toxic drugs is not feasible. Background.LKB1 mutations are the underlying genetic abnormality causing Peutz?Jeghers syndrome (PJS) and are a potential target for everolimus. In this phase II study, the efficacy of everolimus on polyp and tumor growth in PJS patients was investigated. Methods.Adult patients with a proven LKB1 mutation and who were suitable for everolimus treatment were included in two different PJS cohorts: (a) patients with unresectable malignancies and (b) patients with high?risk polyps. Treatment in both groups was oral everolimus, 10 mg daily. Response rates were primary endpoints for both cohorts. Results.Between October 2011 and April 2016, only two patients were enrolled, one in each cohort. A 49?year?old patient with advanced pancreatic cancer in cohort 1 was progressive after 2 months. A 52?year?old male patient in cohort 2 experienced severe toxicity and refused treatment after 4 months, even though endoscopy suggested stabilization of polyps. Adverse events included dental inflammations, mucositis, and rash. In 2016, the trial was aborted for lack of accrual, despite extensive accrual efforts in an area where PJS is highly prevalent and care is highly centralized. Conclusion.Due to accrual problems, no conclusions can be drawn about the value of everolimus in PJS treatment, questioning the feasibility of this agent for chemoprevention. äChemoprevention in Patients with Peutz?Jeghers Syndrome: Lessons Learn(epmc).pdf DeepDyve Pubget Overpricing